



Enhanced Annual Drug List Updates

April 2024

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
BREO ELLIPTA (fluticasone furoate-vilanterol aero powd ba 50-25 mcg/act)	Brand	Addition, Preferred Status
CIBINQO (abrocitinib tab 100 mg)	Brand	Addition, Preferred Status
CIBINQO (abrocitinib tab 200 mg)	Brand	Addition, Preferred Status
CIBINQO (abrocitinib tab 50 mg)	Brand	Addition, Preferred Status
KALYDECO (ivacaftor packet 5.8 mg)	Brand	Addition, Preferred Status
OPVEE (nalmeferene hcl nasal spray 2.7 mg/0.1ml (base equiv))	Brand	Addition, Preferred Status
PAXLOVID (nirmatrelvir tab 10 x 150 mg & ritonavir tab 10 x 100 mg pak)	Brand	Addition, Preferred Status
PAXLOVID (nirmatrelvir tab 20 x 150 mg & ritonavir tab 10 x 100 mg pak)	Brand	Addition, Preferred Status
TIBSOVO (ivosidenib tab 250 mg)	Brand	Addition, Preferred Status
ZENPEP (pancrelipase (lip-prot-amyl) dr cap 60000-189600-252600 unit)	Brand	Addition, Preferred Status

A division of Health Care Service Corporation, a Mutual Legal Reserve Company, an independent licensee of the Blue Cross Blue Shield Association. Blue Cross and Blue Shield of Texas (BCBSTX) contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.